Know Cancer

or
forgot password

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents


N/A
18 Years
N/A
Open (Enrolling by invite only)
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents


Inclusion Criteria:



- Alpha-feto protein > 400 ng / mL or

- prior ultrasound with mass suspicious for hepatic malignancy or.

- clinical risk of hepatocellular carcinoma or

- prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Exclusion Criteria:

- Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement
within three months of the MR study

- Previous diagnosis of hepatic malignancy

- Any conditions that would discount the ability to have an MRI scan

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Rizwan Aslam, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

San Francisco VA Medical Center

Authority:

United States: Federal Government

Study ID:

10-03278

NCT ID:

NCT01341132

Start Date:

May 2011

Completion Date:

Related Keywords:

  • Hepatocellular Carcinoma
  • HCC
  • Hepatocellular Carcinoma
  • MRI
  • Liver
  • Carcinoma
  • Fibrosis
  • Carcinoma, Hepatocellular

Name

Location

San Francisco VA Medical CenterSan Francisco, California  94110